Legorreta Pablo G. 4

What Happened
Pablo G. Legorreta, CEO, Chairman and Director of Royalty Pharma plc (RPRX), was granted 157,828 Class A Ordinary Shares on February 11, 2026 in connection with the settlement of Equity Performance Awards. The shares were acquired at $0.00 per share (award settlement), so no cash was paid. The Form 4 was filed on February 13, 2026.

Key Details

• Transaction date: 2026-02-11; Form 4 filed: 2026-02-13 (appears timely).
• Transaction type/code: Award/Acquisition (A); price reported: $0.00; total cash paid: $0.
• Footnote: Acquisition is exempt under Rule 16b-3 in connection with settlement of Equity Performance Awards (per F1).
• Shares owned after transaction: not specified on the Form 4; see remarks below for related holdings.
• No indication of a market purchase or sale—this was a compensation award (not a 10b5-1 sale or open-market buy).

Context
Equity awards like this are a common form of executive compensation and do not necessarily signal a buying or selling preference. The filing also notes that the Reporting Person and family vehicles hold limited partnership interests exchangeable into a large number of underlying shares: RPI US Partners 2019, LP interests exchangeable into 73,495,660 Class A Ordinary Shares, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 13,356,742 Class A Ordinary Shares (the Class E shares are subject to vesting conditions). The Rule 16b-3 exemption simply reflects that this settlement is a routine, board-approved compensatory award.